Ionis Pharmaceuticals (IONS) Gains FDA Approval for HAE Drug, Piper Sandler Lifts Target

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) ranks among the best mid-cap stocks with huge upside potential. On August 22, following the FDA approval of the company’s treatment for hereditary angioedema (HAE), Piper Sandler maintained its Overweight rating on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and raised its price target from $62 to $65.

Dawnzera (donidalorsen), Ionis’ second independent product approval and launch, was approved by the FDA for use in adult and pediatric HAE patients aged 12 and above.

In this context, the firm emphasized Ionis’s skilled sales team in immunology and allergy, with a focus on the HAE market. Given that HAE is largely seen as a market where patients switch between therapies, this expertise might prove beneficial.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) produces medications for serious medical conditions, with a specific emphasis on cardiovascular and neurological disorders.

While we acknowledge the potential of IONS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.